Photocure ASA · OSL:PHO

Photocure ASA — Q3 2005 Earnings Presentation

18 slides from Photocure ASA's earnings presentation, Oct 28, 2005

  1. Slide 1: PhotoCure ASA Presentation of Third Quarter 2005

    PhotoCure ASA Presentation of Third Quarter 2005 28 October 2005

  2. Slide 2: Highlights third quarter 2005

    Highlights third quarter 2005 „ Hexvix® – First commercial sales in Nordic region – Negotiations with potential licensees outside the Nordic region „ Metvix® – European sales volumes continue to grow – Approval for BCC and AK in Brazil – Agreement with FDA on Aktilite studies for US approval „ Devel

  3. Slide 3: Hexvix - a breakthrough in bladder cancer diagnostics

    HEXVIX® - a breakthrough in bladder cancer diagnostics

  4. Slide 4: Hexvix - business update

    Hexvix - business update „ Building long-term market position – Negotiating licence agreement – Introduction in Nordic countries „ Reinforcing a solid scientific platform – New European guidelines recommend Hexvix for diagnosis of bladder cancer (CIS) – Article in Journal of Urology: 1 of 5 bladder

  5. Slide 5: Hexvix - procedure in the operating room

    Hexvix - procedure in the operating room One kit Preparation Instillation in bladder Visualisation of bladder cancer per patient of solution followed by cysto- scopy after one hour

  6. Slide 6: Hexvix - key medical benefits

    Hexvix - key medical benefits „ Diagnosis of more patients with CIS „ Diagnosis at earlier stages „ Diagnosis of more papillary lesions – 1 of 4 tumors overlooked when not using Hexvix „ Improves patient management – Improved diagnosis leads to more adequate treatment – Improved quality of life for

  7. Slide 7: Metvix - roll out continues

    METVIX® - roll out continues

  8. Slide 8: Metvix - Galderma sales increase

    Metvix - Galderma sales increase Metvix Sales - Galderma 2003 - 2005 „ Sales increase in Metvix tubes of 57 % vs Q3 2004 7000 „ Sales revenues of NOK 4.1 mill 6000 in Q3 (NOK 4.7 mill) mainly due to lower Aktilite sales 5000 4000 „ Approval in Brazil Units 3000 „ 42 Aktilite lamps sold to 2000 Galde

  9. Slide 9: Metvix - Nordic sales increase

    Metvix - Nordic sales increase Metvix Sales - Nordic 2003 - 2005 „ Sales increase in units of 20 % 4000 vs Q3 2004 3500 3000 „ Sales revenues of NOK 3.2 mill 2500 in Q3 (NOK 3.5 mill) mainly Units 2000 due to lower Aktilite sales 1500 1000 500 0 Q1 Q2 Q3 Q4 Per quarter 2003 2004 2005

  10. Slide 10: Metvix - gaining momentum with over patients in 2005

    Metvix - gaining momentum with over 100 000 patients in 2005 „ Treatment of over 100 000 patients with an estimated retail value above € 10 million in 2005 „ Avg. 2-3 patients per 2g tube „ The pharmaceutical non- melanoma skin cancer market increasing by 25 % annually „ Launched in 13 European coun

  11. Slide 11: Metvix - agreement with FDA regarding Aktilite in USA

    Metvix - agreement with FDA regarding Aktilite in USA „ Regulatory requirements: – Two vehicle-controlled trials – No bridging to Curelight – 160 patients – Submit file with 3-month follow-up data „ Estimated cost 25 MNOK in total „ Planned timeline: – 2006: Conduct studies in US and EU – 2007-H1: F

  12. Slide 12: Metvix - acne: development of a new indication

    Metvix - acne: development of a new indication „ Proof-of-concept study completed - presentation at the annual meeting of European Society for Photodynamic Therapy (Euro-PDT) in first half 2006 „ Development plan: – Target indication: Moderate to severe acne – Target market: USD 1 bill in annual sal

  13. Slide 13: Financial Statements (Group)

    Financial Statements (Group)

  14. Slide 14: Profit & Loss (group)

    Profit & Loss (group) In accordance with IFRS 2005 2004 2005 2004 2004 30.06 - 30.09 30.06 - 30.09 All figures in NOK 1,000 01.01 - 30.09 01.01 - 30.09 01.01 - 31.12 7 322 8 134 Sales revenues 24 994 27 920 36 855 3 908 29 228 Signing fee and milestone revenues 11 725 37 045 40 954 11 230 37 362 Sal

  15. Slide 15: Balance Sheet (group)

    Balance Sheet (group) In accordance with IFRS 2005 2004 2004 Figures in NOK 1,000 30.09 30.09 31.12 Machinery & equipment 2 273 2 155 2 080 Financial fixed assets - 6 250 - Inventory 14 591 19 172 17 533 Receivables 20 999 18 175 16 146 Securities 65 765 117 644 111 219 Cash & cash equivalents 15 21

  16. Slide 16: Cash Flow Statement (group)

    Cash Flow Statement (group) In accordance with IFRS Nine months ended 2004 30.09.2005 30.09.2004 01.01 - 31.12 Loss before tax -25 101 -17 698 -45 323 Interest paid -50 -56 -103 Other operational items -31 962 -11 130 -4 822 Net cash flow from operations -57 113 -28 884 -50 248 Cash flow from invest

  17. Slide 17: Goals and Milestones

    Goals and Milestones

  18. Slide 18: Strategic and operational goals

    Strategic and operational goals (Presented in February 2005) „ Launch Hexvix program STATUS: – Complete MRP procedure in EU/EEA countries YES – March 2005 – Launch in Nordic countries YES – June 2005 – File NDA in US YES – June 2005 – Secure licensing partner Negotiations ongoing „ Continue investin

PhotoCure — Q3 2005 Earnings Presentation on 6ix